Genetic evidence that higher central adiposity causes gastro-oesophageal reflux disease: a Mendelian-randomization study by Beaumont, Robin N. et al.
Original Article
Genetic evidence that higher central adiposity
causes gastro-oesophageal reflux disease: a
Mendelian-randomization study
Harry D Green,1,2 Robin N Beaumont,1 Andrew R Wood,1
Benjamin Hamilton,2 Samuel E Jones,1 James R Goodhand,2
Nicholas A Kennedy,2 Tariq Ahmad,2 Hanieh Yaghootkar,1
Michael N Weedon,1 Timothy M Frayling1 and Jessica Tyrrell 1*
1Genetics of Complex Traits, University of Exeter Medical School, Exeter, UK and 2IBD
Pharmacogenetics, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
*Corresponding author. Genetics of Complex Traits, University of Exeter Medical School, Exeter, UK. E-mail:
j.tyrrell@exeter.ac.uk
Accepted 26 May 2020
Abstract
Background: Gastro-oesophageal reflux disease (GORD) is associated with multiple risk
factors but determining causality is difficult. We used a genetic approach [Mendelian ran-
domization (MR)] to identify potential causal modifiable risk factors for GORD.
Methods: We used data from 451 097 European participants in the UK Biobank and de-
fined GORD using hospital-defined ICD10 and OPCS4 codes and self-report data
(N¼ 41 024 GORD cases). We tested observational and MR-based associations between
GORD and four adiposity measures [body mass index (BMI), waist–hip ratio (WHR), a
metabolically favourable higher body-fat percentage and waist circumference], smoking
status, smoking frequency and caffeine consumption.
Results: Observationally, all adiposity measures were associated with higher odds of
GORD. Ever and current smoking were associated with higher odds of GORD. Coffee con-
sumption was associated with lower odds of GORD but, among coffee drinkers, more
caffeinated-coffee consumption was associated with higher odds of GORD. Using MR,
we provide strong evidence that higher WHR and higher WHR adjusted for BMI lead to
GORD. There was weak evidence that higher BMI, body-fat percentage, coffee drinking
or smoking caused GORD, but only the observational effects for BMI and body-fat per-
centage could be excluded. This MR estimated effect for WHR equates to a 1.23-fold
higher odds of GORD per 5-cm increase in waist circumference.
Conclusions: These results provide strong evidence that a higher waist–hip ratio leads to
GORD. Our study suggests that central fat distribution is crucial in causing GORD rather
than overall weight.
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Introduction
Gastroesophageal reflux disease (GORD) has been defined
as ‘symptoms or complications resulting from the reflux of
gastric contents into the oesophagus or beyond, into the
oral cavity (including larynx) or lung’.1 GORD is common,
with typical symptoms of heartburn and acid regurgitation
reported weekly by 13.3% of the general population.2
Numerous modifiable risk factors have been demon-
strated to associate with GORD, but the majority of these
have only been reported in observational studies, which
are prone to confounding and reverse causality. For exam-
ple, there is extensive observational evidence that adiposity
[as measured by body mass index (BMI)] is associated with
GORD. A large meta-analysis of 22 studies reports a 1.73-
fold (1.46–2.06) increased risk of GORD in obese individ-
uals (defined by BMI>30 kg/m2)2 and a recent large
genome-wide association study (GWAS) of GORD reports
a genetic correlation between GORD and BMI.3 The litera-
ture also provides evidence that other measures of adipos-
ity correlate with GORD phenotypes including waist
circumference with reflux symptoms4 and waist–hip ratio
(WHR) with both oesophageal inflammation (erosive re-
flux disease) and Barrett’s Oesophagus.5 Several observa-
tional studies report an attenuation in the BMI association
when BMI and WHR are included in multivariable models,
suggesting that body-fat distribution may be an important
factor in GORD.6
Patients commonly report that both alcohol and coffee
consumption exacerbate GORD symptoms. However, a
2014 meta-analysis containing 15 case–control studies
reported no significant association between GORD and
coffee consumption,7 whereas the largest study included
(n¼ 3153) reported a negative association.8 A recent
(2019) meta-analysis of alcohol consumption and GORD
reported conflicting evidence but suggested a positive asso-
ciation.9 Smoking is also frequently implicated in GORD,
with studies demonstrating associations between GORD
and (i) smoking duration and lifetime number of cigarettes
smoked8 and (ii) both smoking history and current
smoking status.10 Psychological factors such as stress10
and depression11 have both been reported to be associated
with GORD, as well as miscellaneous factors such as wear-
ing a belt too tightly,12,13 sugar intake,14 salt intake8 and
heavy physical workload.15
Mendelian randomization (MR; Figure 1) is a technique
used to infer causal relationships between an exposure and
an outcome by using genetic variants associated with the
exposure. The variants associated with the exposure (e.g.
BMI) can be used as an unconfounded proxy for the expo-
sure, as their inheritance is random at conception. This
method is now extensively used to infer causal pathways
and has been used to study the impact of BMI on oesopha-
geal adenocarcinoma and Barrett’s Oesophagus.16 In this
study, genetically predicted BMI was demonstrated to in-
dependently increase the risk of both oesophageal adeno-
carcinoma and Barrett’s Oesophagus, but the power of the
study was limited by the low numbers of cases.
Furthermore, this study did not include other measures of
adiposity such as WHR.
Here, we sought to assess the causal role of obesity
measures [BMI, WHR, body-fat percentage (BFP) and a
measure of higher but metabolically favourable adiposity]
and lifestyle factors (smoking and caffeine) on the risk of
GORD in up to 41 024 cases and 410 073 control individu-
als of European ancestry enrolled in the UK Biobank. First,
we report observational associations to check for consis-
tency with previous literature. Then, we used MR
approaches to determine which of these associations have
a likely causal role in GORD and which are potentially
confounded at the observational level.
Methods
Participants
The UK Biobank is a large-scale study that aims to investi-
gate the genetic and environmental basis of disease. Over
500 000 participants aged between 40 and 69 years were
Key Messages
• Body mass index (BMI) is widely reported to associate with gastroesophageal reflux disease (GORD).
• Previous studies on lifestyle factors such as alcohol and smoking have reported inconsistent findings.
• Existing evidence for associations between obesity and lifestyle factors with GORD come from observational studies
that are prone to confounding factors.
• Our results show that the widely reported associations between GORD and BMI are confounded by measures of cen-
tral adiposity.
• We demonstrate that central adiposity is the more important causal risk factor for GORD.
• These results suggest that clinicians should advise patients at risk of GORD to reduce their waist size.
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recruited between 2006 and 2010. Data collected include
demographics, International Classification of Diseases
10th Revision (ICD10) hospital coding, medication
records, anthropometric measures and a questionnaire
containing lifestyle and mental-health factors. All partici-
pants have been genotyped, 450 000 using the
Affymetrix Axiom UK Biobank array and 50 000 using
the UK BiLEVE array. More detail on recruitment, demo-
graphics and data availability17 and on the collection and
imputation of genomic data18 can be found elsewhere.
We defined 451 097 individuals of European descent us-
ing principal component analysis.19 We used well-imputed
single nucleotide polymorphisms (SNPs) in the 1000
Genomes Cohort to project principal components from
1000 G and UK Biobank into the same space and clustered
by the first four principal components to define Europeans.
We also defined a subset of 379 713 unrelated individuals
of European ancestry. Related individuals were defined
using a KING Kinship20 to exclude those third-degree
relatives or closer. An optimal list of unrelated individuals
was generated by preferentially removing individuals with
the maximum number of relatives to allow maximum
numbers of individuals to be included; e.g. if A was related
to B and C, but B and C were not, A was removed. For a
simple pair, one individual was removed at random.
Ancestral principal components were then generated
within these identified individuals for use in subsequent
analyses.
Patient and public involvement. This study uses data
from the UK Biobank resource. Details of patient and pub-
lic involvement in the UK Biobank are available online
(https://www.ukbiobank.ac.uk/wp-content/uploads/2011/07/
Summary-EGF-consultation.pdf? phpMyAdmin¼trmKQlYd
jjnQIgJ%2CfAzikMhEnx6). Patients were not specifically
involved with setting the research questions and outcome
measures or asked to contribute to the interpretation or pub-
lication of results. The results will not be directly dissemi-
nated to study participants, but the UK Biobank’s website
contains summaries of key findings.
GORD
We derived four GORD variables—one for use in primary
analyses and three sensitivity analyses, each with increasing
levels of certainty around the diagnosis of GORD. ICD10
and OPCS Classification of Interventions and Procedures
version 4 (OPCS4) operation codes were obtained from the
Hospital Episode Statistics (HES; https://digital.nhs.uk/
data-and-information/data-tools-and-services/data-services/
hospital-episode-statistics). Self-reported conditions, risk
factors and medication data were obtained from a verbal
interviews at the UK Biobank Assessment Centre.
For the primary analysis, cases were defined as having
any of the following:
• a self-report code of 1138 (GORD/gastric reflux) in the
non-cancer variable (n_20002_*);
• an ICD10 code of K21.9 (GORD without esophagitis) or
K21.0 (GORD with esophagitis) in HES;
• an OPCS4 operation code of G24 (anti-reflux opera-
tions) or G25 (revision of anti-reflux operations) in the
HES data.
All other individuals of European descent were included
as controls for the primary analysis. This resulted in
Figure 1 Principle of Mendelian randomization.
If a specific risk factor [e.g. body mass index (BMI)] causes gastroesophageal reflux disease (GORD), genetic variants associated with that risk factor
will also be associated with GORD. The genetic variants must not be associated with any other variables that could potentially confound the BMI–
GORD association, such as lifestyle or environmental factors. Using the estimate of the genetic–BMI association (ŵ) and the apparent genetic–GORD
association (x̂), we can infer the causal effect of BMI on GORD (ŷ ¼ x̂=ŵ), which is expected to be free from confounding. If ŷ is different to the obser-
vational associations, and assuming the core assumptions hold, this would suggest that the observational associations are confounded.
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33 969 cases vs 345 744 controls in unrelated individuals
and 41 024 cases vs 410 073 controls in the related individu-
als. We also repeated this analysis using only the incident
cases in the UK Biobank (10 664 cases vs 340 373 controls).
In Sensitivity Analysis 1, cases defined from only a self-
reported definition of GORD were excluded. Controls tak-
ing medication common for reflux treatment (i.e. proton
pump inhibitors and H2-receptor blockers) and controls
who had had a diagnostic endoscopic examination of the
upper gastrointestinal tract (OPCS4 code G45) were ex-
cluded due to the chance of these individuals having
undiagnosed reflux. Sensitivity Analysis 1 contained
21 054 cases and 288 233 controls (25 372 cases and
340 996 in related individuals).
In Sensitivity Analysis 2, cases of GORD without esoph-
agitis were excluded, leaving 10 135 cases and the same
288 233 controls.
In Sensitivity Analysis 3, we kept only the cases that had
undergone anti-reflux surgery, excluding those with no other
confirmation of GORD, leaving only 758 cases and 288 233
controls. The exclusions for unrelated and related Europeans
are summarized in Figure 2 and Supplementary Figure 1,
available as Supplementary data at IJE online, respectively.
Exposure variables
In this study, we investigated the role of seven exposure
variables. The exposure variables are described briefly
below:
• BMI—BMI was calculated using the standard method of
weight divided by height squared (kg/m2).
• WHR—we used both a) WHR and b) WHR adjusted for
BMI as measures of central adiposity. Both measures
were derived as detailed by the GIANT consortium.21
Figure 2 Definitions of gastroesophageal reflux disease (GORD).
Flowchart showing definitions of phenotypes with numbers of people in each category for the 379 713 unrelated individuals in the UK Biobank, using
ICD10 (International Classification of Diseases 10th Revision) codes, endoscopy status, proton pump inhibitor and H2-receptor blocker use to further
refine the phenotype. The same flowchart for all 450 000 Europeans is given in Supplementary Figure 1, available as Supplementary data at IJE on-
line. The farther down the sensitivity analysis, the greater the confidence we have that the cases are true GORD cases.
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• Coffee consumption—coffee consumption was reported
as number of caffeinated-coffee cups drunk per day,
from a questionnaire. A coffee drinker in the observa-
tional analysis is defined as drinking >0 caffeinated-
coffee cups per day.
• Cigarettes per day—for former and current smokers, a
pack-years variable was derived from the number of cig-
arettes smoked per day and the number of years an indi-
vidual had smoked.
• BFP—BFP was estimated by an impedance measurement
by the UK Biobank.
• Favourable adiposity—favourable adiposity was derived
genetically and is detailed in the ‘Genetic variants’
section.
All continuous exposure variables were inverse-
normalized prior to further analyses.
Observational analysis
We utilized logistic-regression models to investigate the re-
lationship between a range of demographic or predictor
variables and GORD. We calculated the odds of GORD
per unit change in the predictors and demographics. Age
and sex were included as covariates in all models. These
tests were repeated using Sensitivity Analyses 1 and 2 to
check for directional consistency in a smaller but more
well-defined cohort.
Genetic variants
Imputation of genetic variants and associated quality con-
trol was performed centrally by the UK Biobank.18,22 For
MR, genetic variants were selected from the UK Biobank
imputation data set. Variants were excluded if imputation
quality (INFO) was <0.9 or the minor allele frequency was
<0.1%.
For each exposure trait (BMI, WHR, BFP, favourable
adiposity, smoking and caffeine consumption), variants
were selected based on reaching genome-wide significance
(P< 5 108) from the largest available GWAS study of
that trait. Where possible, exposure trait GWAS studies
did not include the UK Biobank, as using variants discov-
ered in the UK Biobank for our predictor traits would in-
crease the possibility of statistical bias. The only exception
was the genetic variants for favourable adiposity (variants
that lead to increased weight but improved metabolic
health) where effect sizes were unavailable for a non-UK
Biobank analysis. Although we report waist circumference
(WC) in the observational analyses, we do not report MR
results for WC, because 21 of the 57 SNPs associated with
WC adjusted for BMI were not independent of BMI.
BMI. The genetic variants extracted for BMI and our
genetic risk score (GRS) for BMI utilized a 2015 GWAS of
339 224 individuals that reported 97 genome-wide signifi-
cant loci.23 We excluded sex-specific variants and those
with potential pleiotropy or secondary signals within a lo-
cus and utilized 72 variants.24
WHR. We used two different sets of variants and GRS
for WHR, both derived from a meta-analysis of 694 649
individuals of European ancestry25:
• 382 SNPs associated with WHR;
• 463 SNPs associated with WHR adjusted for BMI.
Favourable adiposity. We used 14 variants for favour-
able adiposity, defined by SNPs that raise BFP but lower
risk of metabolic disease. Further details on how these
SNPs were identified is available elsewhere.26
Caffeine coffee cups per day. For caffeinated-coffee con-
sumption, we used six SNPs from a 2015 genome-wide
meta-analysis of habitual coffee consumption.27
Cigarettes per day. For smoking, we used four SNPs
from a 2010 genome-wide meta-analysis of smoking
behaviour.28
We did not include alcohol in the MR analysis due to
the lack of availability of an appropriate genetic
instrument.
The extracted genetic variants were used to create GRS
for each potential GORD risk factor. Each variant in the
GRS was weighted by its effect size ðbiÞ on the risk factor,
taken from the original GWAS to create a weighted score
ðWs; Equation 1). Ws was then rescaled by the number of
variants (n) and the sum of bi values to calculate the
weighted GRS ðWGRS; Equation 2), which reflects the
number of trait-raising alleles:
Ws ¼
Xn
i¼1
bi  SNPi (1)
WGRS ¼
WS  n
Pn
i¼1
bi
(2)
All genetic instruments were associated with the rele-
vant predictor, with high levels of statistical confidence
and large F-statistics suggesting no weak instrument bias
(in Sensitivity Analysis 3, we kept only those cases that had
undergone anti-reflux surgery, excluding those with no
other confirmation of GORD, leaving only 758 cases and
288 233 controls. The exclusions for unrelated and related
Europeans are summarized in Figure 2 and Supplementary
Table 2, available as Supplementary data at IJE online).
Statistics showing potential pleiotropy between exposure
traits are shown in Supplementary Table 3, available as
Supplementary data at IJE online.
International Journal of Epidemiology, 2020, Vol. 0, No. 0 5
D
ow
nloaded from
 https://academ
ic.oup.com
/ije/advance-article/doi/10.1093/ije/dyaa082/5862926 by guest on 03 N
ovem
ber 2020
MR
We used different MR methods to test the causal role of
seven exposures on GORD. First, we performed standard
one-sample instrumental variable analyses using the GRS
in the unrelated data set of 379 713 individuals. Second,
we investigated the causal relationship using a two-sample
approach in the 451 097 related individuals. In this step,
we explored whether our findings were robust to any po-
tential influence of population stratification by using linear
mixed models as implemented in the BOLT-LMM soft-
ware.29 For both types of MR, the following assumptions
must be met30:
i. The genetic instruments used associate with the expo-
sure trait with a high level of confidence. Here, we
tested this assumption, using linear regression to ex-
plore the association of the GRS with the relevant pre-
dictors in the UK Biobank (Supplementary Table 2,
available as Supplementary data at IJE online).
ii. The genetic instruments are independent of other fac-
tors that affect the outcome. This assumption is vio-
lated if (a) subgroups of the population have both
different genotype frequencies and different distribu-
tions of the outcome or (b) the genetic variants used as
instruments associate with confounders.
iii. The genetic instruments are linked with the outcome
trait only through the respective exposure trait. This
assumption is violated if the genetic instrument or an-
other variant in high linkage disequilibrium has multi-
ple (pleiotropic) effects.
One-sample MR: instrumental variable analysis
This analysis was performed in two stages. First, the asso-
ciation between the exposure and its GRS was assessed
and the predicted values from this regression were saved.
Second, the predicted values were used as the independent
variable (reflecting an unconfounded estimate of variation
in the exposure) and GORD was the dependent variable in
a logistic-regression model. In these models, age, sex, an-
cestral principal components, assessment centre and geno-
typing platform were included as covariates. For WHR, we
further estimated the causal influence of WC by using the
correlation between the WHR adjusted for BMI GRS.
We performed a power calculation for our one-sample
MR analysis using an online power calculator.31 Power to
detect an association at alpha< 0.05 with an odds ratio
greater than or equal to the observational result (Table 1)
was 100% for BMI, WHR adjusted for BMI and WHR;
moderate for BFP and favourable adiposity (81% and
63%); and limited for caffeine and smoking (5% and
13%) (Supplementary Table 2, available as Supplementary
data at IJE online).
Two-sample MR
A two-sample MR approach was utilized in the larger re-
lated subset of individuals, corrected for relatedness using
BOLT-LMM v2.3, which accounts for population struc-
ture as part of the model.29 We extracted the variants for
our seven exposures from the BOLT-LMM GWAS of the
four definitions of GORD. We then performed inverse var-
iance weighted (IVW) instrumental variable analysis and
two further methods that are more robust to potential vio-
lations of the standard MR assumptions (MR-Egger32 and
weighted-median MR33). The two-sample approach
regresses the effect sizes of variant–outcome associations
against the effect sizes of the variant–risk factor associa-
tions. IVW assumes no horizontal pleiotropy (under a
fixed-effects model) or, if implemented under a random-
effects model after detecting heterogeneity among the
causal estimates, that (i) the strength of the association of
the genetic instruments with the risk factor is not corre-
lated with the magnitude of the pleiotropic effects and (ii)
the pleiotropic effects have an average value of zero.
In contrast, the MR-Egger uses a weighted regression
with an unconstrained intercept, thus removing the as-
sumption that all genetic variants are valid instruments.
Hence, this method is less susceptible to potentially pleio-
tropic variants. Weighted-median MR is also more resis-
tant to pleiotropy. This method provides a consistent
estimate of the causal effect if 50% of the information
comes from valid instrumental variables. Given these dif-
ferent assumptions, if all methods are broadly consistent, it
strengthens our causal inference. The R code for the vari-
ous two-sample methods is available in Bowden et al.
201532 and 2016.33
Results
Observational associations
The demographics of GORD cases and controls are sum-
marized in Table 1. Briefly, participants with GORD were
older, more deprived, more likely to be current or former
smokers and smoked more cigarettes per day than controls.
Individuals with GORD were less likely to drink caffein-
ated coffee, although, among coffee drinkers, we see a pos-
itive association with caffeinated-coffee cups per day.
We observed strong observational associations with all
adiposity-related variables: BMI, WHR, WC and BFP.
Higher odds of GORD were noted for a 1-standard-devia-
tion (SD) higher BMI [odds ratio (OR): 1.28, 95% confi-
dence interval (CI): 1.27–1.29], WHR (OR: 1.43, 95% CI:
1.41–1.46), WC (OR: 1.33, 95% CI: 1.31–1.36) and BFP
(OR: 1.53, 95% CI: 1.50–1.55). These observational
results were consistent when more stringent definitions of
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GORD were utilized (Supplementary Table 1, available as
Supplementary data at IJE online).
MR
MR of adiposity-related traits with GORD
Genetic data provided evidence that a higher waist–hip ra-
tio causes GORD with strong statistical confidence; a 1-SD
higher WHR is associated with 1.22 higher odds of GORD
(95% CI: 1.09–1.38; Table 2). Similar associations were
noted when we used WHR adjusted for BMI, with a 1-SD
higher WHR adjusted for BMI causing higher odds of
GORD (OR: 1.19, 95% CI: 1.13–1.26; Table 2). These
results were consistent when using the more stringent defi-
nitions of GORD (Figure 3A; Supplementary Table 4,
available as Supplementary data at IJE online) and when
using only the incident GORD cases (Supplementary
Table 5, available as Supplementary data at IJE online).
The two-sample MR approaches were directionally consis-
tent (Figure 3B and Supplementary Table 6, available as
Supplementary data at IJE online) with limited evidence of
pleiotropy from the MR-Egger method (pintercept> 0.05,
Supplementary Table 5, available as Supplementary data
at IJE online). The WHR adjusted for BMI association
equates to 1.19-fold higher risk of GORD per 4.2-cm
larger WC (1.23-fold per 5 cm) using correlations between
Table 1 Observational associations with gastroesophageal reflux disease (GORD)
Trait Controls GORD cases p-value Odds ratio
(95% confidence
interval)
N 345 744 33 969
Male [N (%)] 159 150 (46.03%) 15 825 (46.59%) 0.67 1.00 (0.98–1.03)
Age (years) 6 SD 57.04 6 8.04 59.25 6 7.4 <11015 1.04 (1.04–1.04)
Townsend Deprivation Index 6 SD 1.5 6 2.98 1.22 6 3.12 <11015 1.11 (1.10–1.13)
Ever smoked [N (%)] Ever: 153 287 (44.35%)
Never: 187 836 (54.33%)
Missing: 4621 (1.34%)
Ever: 17 076 (50.27%)
Never: 16 383 (48.23%)
Missing: 511 (1.5%)
<11015 1.22 (1.19–1.25)
Current smokers [N (%)] Smoker: 32 664 (9.45%)
Non-smoker: 308 459 (89.22%)
Missing: 4621 (1.34%)
Smoker: 3276 (9.64%)
Non-smoker: 30 182 (88.85%)
Missing: 511 (1.5%)
3107 1.10 (1.06–1.15)
Cigarettes per day 6 SD 18.4 6 10.09 19.8 6 10.91 <11015 1.12 (1.10–1.14)
Caffeinated-coffee drinkers [N (%)] Drinker: 221 046 (63.93%)
Non-drinker: 71 128 (20.57%)
Missing: 53 570 (15.49%)
Drinker: 19 971 (58.79%)
Non-drinker: 8093 (23.82%)
Missing: 5905 (17.38%)
<11015 0.79 (0.77–0.81)
Caffeinated-coffee cups per day 6 SD 2.63 6 2.05 2.64 6 2.12 0.003 1.02 (1.01–1.04)
Body mass index (kg/m2) 6 SD 27.26 6 4.74 28.59 6 4.93 <11015 1.28 (1.27–1.29)
Waist–hip ratio 6 SD 0.87 6 0.09 0.89 6 0.09 <11015 1.43* (1.41–1.46)
Waist–hip ratio (males) 6 SD 0.87 6 0.09 0.95 6 0.07 <11015 1.36 (1.33–1.39)
Waist–hip ratio (females) 6 SD 0.81 6 0.07 0.84 6 0.07 <11015 1.49 (1.46–1.52)
Waist circumference 6 SD 89.95 6 13.51 93.68 6 13.07 <11015 1.33 (1.31–1.36)
Body-fat percentage 6 SD 31.12 6 8.48 33.26 6 8.69 <11015 1.53 (1.50–1.55)
Table showing statistical differences in demographics between our primary GORD definition and controls in the UK Biobank. All p-values and odds ratios
were calculated adjusted for age and sex. Cigarettes per day and caffeinated-coffee units were only defined in smokers and coffee drinkers. N for continuous varia-
bles: Coffee—241 016; Smoking—122 363; Townsend Deprivation Index—379 245; body mass index—378 214; waist–hip ratio—378 974; waist–hip ratio
(male)—174 633; waist–hip ratio (female)—204 341; waist circumference—379 049; body-fat percentage—372 848. *when additionally adjusted for body mass
index, OR¼ 1.29 (1.27–1.31).
Table 2 Estimates of associations between risk factors and
Gastroesophageal Reflux Disease (GORD) using Mendelian
randomization
Exposure N Odds ratio p-value
Caffeinated-coffee
cups per day
241 016 1.18 (0.88–1.58) 0.28
Cigarettes per day 112 363 1.20 (0.84–1.72) 0.32
BMI 378 214 1.04 (0.95–1.14) 0.36
WHR adjusted for BMI 378 974 1.19 (1.13–1.26) 4.5  1011
WHR 378 090 1.22 (1.09–1.38) 7.2  104
BFP 372 848 1.14 (0.94–1.38) 0.17
Favourable adiposity 372 848 1.10 (0.87–1.39) 0.43
Results of Mendelian randomization within the UK Biobank to show the
causal effect of coffee, smoking, body mass index (BMI), waist–hip ratio
(WHR), body-fat percentage (BFP) and favourable adiposity on GORD.
Odds ratios are reported per standard deviation increase in the exposure trait.
Coffee and cigarette analyses were performed only for drinkers/smokers.
Sensitivity analyses are given in Supplementary Table 4, available as
Supplementary data at IJE online.
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the WHR adjusted for BMI GRS and WC (Supplementary
Table 7, available as Supplementary data at IJE online).
Genetic data provided limited evidence that higher BMI
(OR: 1.04, 95% CI: 0.95–1.14), BFP (OR: 1.14, 95% CI:
0.94–1.38) or favourable adiposity (OR: 1.10, 95%
CI: 0.87–1.39) causes GORD (Table 2). The 95% CIs for
BMI do not cross the observational result, suggesting
the observational result is confounded. These results were
consistent when the more refined phenotypes were used
(Supplementary Table 4, available as Supplementary data
at IJE online, Figure 3 and Supplementary Figure 2, avail-
able as Supplementary data at IJE online) and when only
the incident cases were included (Supplementary Table 5,
available as Supplementary data at IJE online). The
results from the more pleiotropy-resistant methods were
directionally consistent for BFP, but not for BMI
(Supplementary Table 5, available as Supplementary data
at IJE online), where the point estimate for Egger was in
the opposite direction.
MR for the role of smoking and coffee drinking in GORD
We also found limited evidence that smoking (OR: 1.20,
95% CI: 0.84–1.72; Table 2) or caffeine consumption
(OR: 1.18, 95% CI: 0.88–1.58; Table 2) causes GORD.
These results were consistent with the more refined defini-
tions of GORD (Supplementary Table 4, available as
Supplementary data at IJE online). The point estimates
from the MR analyses for the odds of GORD for both
smoking and caffeine consumption were stronger than the
respective observational results and directionally consistent.
Discussion
Principal findings
This study tested the causal role of adiposity and lifestyle-
related exposures on GORD. First, we confirmed observa-
tional links between various adiposity measures (BMI,
WC, WHR and BFP) and lifestyle factors (smoking and
caffeine) with GORD in a large European population.
Second, we used MR to provide evidence that higher WHR
causes GORD, whilst there was little evidence for higher
BMI causing GORD. We demonstrated that a 5-cm larger
WC causes 1.23 higher odds of GORD. In contrast, for
BMI, we could exclude an OR effect of >1.15 per 5 kg/m2
higher BMI. This contrasts with observational studies in
which BMI is strongly associated with GORD.2,34–36 This
study suggests that the observed relationship between
higher BMI and GORD is principally driven by fat distri-
bution, and central adiposity is a crucial factor.
Our MR results for BMI challenge the commonly held
belief, inferred from observational studies and meta-
analyses, that higher BMI causes GORD.2,34–36 The MR
results were consistent with previous multivariate analyses
that highlighted the importance of WHR in both erosive
esophagitis and Barret’s Oesophagus. For example, in a
small Korean population (500 cases), BMI was shown to
be not associated with erosive esophagitis in multivariable
models including WHR5 and, in a study of Barrett’s
Oesophagus (N¼ 193), the BMI association was greatly at-
tenuated, whereas WHR remained strong.6 Our findings in
a large European population provide strong evidence for
the role of WHR in GORD. ORs were similar (within the
95% CI) when using only the incident cases and we still
observe a Bonferonni significant p-value for WHR adjusted
for BMI, but not for BMI (Supplementary Table 6, avail-
able as Supplementary data at IJE online).
The pathophysiology of GORD is complex and a num-
ber of factors have been implicated, including diminished
gastric volume, increased intragastric pressure and de-
creased lower oesophageal sphincter pressure (secondary
to chronic antral compression/displacement).37 Arguably,
all of the factors are more feasibly driven by central adi-
posity rather than overall body weight. Our results are
consistent with the proposed mechanisms behind waist-
belt compression causing GORD by impairing oesophageal
clearance,12 the increased incidence of reflux during later
trimesters of pregnancy and variable GORD-symptom im-
provement following surgical weight-loss procedures de-
spite BMI reduction.38
Whereas BMI is a commonly used and simple-to-
calculate clinical measure, its use is limited by an inability to
differentiate between fat and muscle mass.39 Additionally,
as BMI may change without an alteration in the abdominal-
fat distribution, our findings strongly support WHR, or
more simply monitoring WC, as a more clinically useful
measure for stratifying obesity-related GORD over BMI.
This study provided little evidence for a causal role for
either smoking or caffeine consumption in GORD.
However, these results were limited by the availability of
only a small number of variants strongly and specifically
associated with smoking heaviness and caffeine consump-
tion. However, for both smoking (cigarettes per day) and
caffeinated-coffee cups per day, the 95% CIs crossed both
the respective observational point estimate and the null hy-
pothesis. This does not provide robust evidence of either
an association or confounding at the observational level or
in previous research.8
Strengths and weaknesses
One of the major strengths of this study was our large sam-
ple size, including 451 097 individuals, with 41 024 cases
of GORD. This was similar in size to a recent meta-analysis
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Figure 3 Forest plots of adiposity variables.
(A) Comparison of analysis methods: showing the observational associations with gastroesophageal reflux disease (GORD), one-sample Mendelian
randomization (MR) and two-sample MR associations (instrumental variable, weighted-median and Egger methods) for body mass index, waist–hip
ratio and waist–hip ratio adjusted for body mass index in our primary analysis (all GORD). (B) Sensitivity analyses for the one-sample MR results
showing similar results across all four analyses. On the right-hand axes are odds-ratio point estimates and 95% confidence intervals. All GORD,
GORD (no self-report), GORD with erosive oesophagitis (EO) and Antireflux Surgery refer to primary Sensitivity Analyses 1, 2 and 3, respectively, de-
scribed in Figure 2.
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exploring GORD risk factors, which included a pooled
population of 460 984 and a prevalence of 13.3% (approxi-
mately 61 310 cases).2 The linked health data in the UK
Biobank enabled us to perform sensitivity analyses with
stricter case definitions than in the meta-analysis (GORD
vs weekly reflux symptoms) and explore the associations
with risk factors in much larger numbers (only 22/108 stud-
ies in the meta-analysis reported BMI, whilst 33/108
reported smoking status). This is the first study to perform
MR to assess the causality of reported GORD risk factors
and, with the sample size available, provided sufficient
power to provide strong evidence for a likely causal role of
higher WC rather than overall BMI on GORD.
We acknowledge some limitations with the study de-
sign. This study uses the UK Biobank data, which were col-
lected from individuals aged between 37 and 73 years
living in the UK with a bias towards healthy individuals.
As such, the results of this study may not be generalizable
to other age ranges. Further, we stratified the data to only
include people of European ancestry, so results may not be
generalizable to other ethnic groups. Supplementary Table
3, available as Supplementary data at IJE online, demon-
strates that pleiotropy may be a confounding factor for the
one-sample MR analysis; e.g. the BMI GRS associates with
smoking and WHR adjusted for BMI associates with BFP.
However, our main results are consistent when using
pleiotropy-resistant two-sample MR methods (MR-Egger
and IVW) and we observe no significant p-values for the
MR-Egger intercept for either BMI or WHR adjusted for
BMIs. Our primary analysis used self-reported GORD sta-
tus and so is potentially unreliable, although our results
were consistent across all sensitivity analyses, including
those using disease-coding status from hospital records
(ICD10). Finally, as our MR analysis relies on robust ge-
netic associations with the risk factor, we were limited in
what we could study. Whilst the WHR and BMI genetic
variants were strong instruments for MR, achieving 100%
power to detect an association with the observational odds
ratio at p< 0.05, the genetic variants for smoking and caf-
feine were weaker and therefore these analyses were
underpowered.
Implications
Given the increasing prevalence of obesity in younger peo-
ple, understanding the role of lifelong exposure to higher
adiposity in GORD is crucial. Here, we have demonstrated
that the most important adiposity-related risk factor for
GORD is not body weight, but fat distribution.
Our results highlight the importance of a healthy body
shape to reduce the risk of GORD and the importance of
recording WHR when studying GORD. We provide
evidence that, for individuals with GORD attempting to al-
leviate symptoms by losing weight, a reduction in WC is a
better measure of progress than loss of overall body
weight. In light of these results, more research is needed on
the causal role of WHR in other related conditions.
Supplementary data
Supplementary data are available at IJE online.
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